Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 11:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 225 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: AZD 2281 Clear all
Active, not recruiting Phase 2 Interventional

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

NCT03375307
View directory record Official record
Conditions
Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
17
States / cities
Encinitas, California • Irvine, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Completed No phase listed Observational

A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer

NCT05775549
View directory record Official record
Conditions
Advanced Ovarian Cancer
Interventions
None (Observational Study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
7
States / cities
Tampa, Florida • Shreveport, Louisiana • Annapolis, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 10, 2026, 11:33 AM EDT
Completed Phase 1 Interventional

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

NCT03205176
View directory record Official record
Conditions
Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
AZD5153, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 10, 2026, 11:33 AM EDT
Recruiting Phase 1 Interventional

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

NCT06856499
View directory record Official record
Conditions
Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Cirtuvivint, Olaparib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT03079687
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Duarte, California • Newport Beach, California • Roseville, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Sep 10, 2026, 11:33 AM EDT
Recruiting Phase 2 Interventional

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

NCT04683679
View directory record Official record
Conditions
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
Interventions
Pembrolizumab, Olaparib, Radiation
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Terminated Phase 2 Interventional Results available

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

NCT04336943
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Durvalumab, Olaparib, Quality-of-Life Assessment, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 10, 2026, 11:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

NCT04086485
View directory record Official record
Conditions
Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Neoplasms
Interventions
Lu-177-DOTATATE, Olaparib, Ga dotatate scanning, FDG-PET scanning, Amino Acid infusion
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

NCT03317392
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Olaparib, Quality-of-Life Assessment, Radium Ra 223 Dichloride
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
22
States / cities
La Jolla, California • Sacramento, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

NCT02345265
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cediranib Maleate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
20
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cediranib Maleate, Computed Tomography, Echocardiography Test, Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
337
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 256 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

NCT00516802
View directory record Official record
Conditions
Melanoma Neoplasms
Interventions
KU-0059436 (AZD2281)(PARP inhibitor), dacarbazine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2009 · Synced Sep 10, 2026, 11:33 AM EDT
Recruiting Phase 1 Interventional

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

NCT04701645
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Fallopian Tube Cancer Stage IV, Fallopian Tube Cancer Stage III
Interventions
Microdevice
Combination Product
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

NCT03737643
View directory record Official record
Conditions
Advanced Ovarian Cancer
Interventions
Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
1,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
26
States / cities
Foothill Ranch, California • Los Angeles, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Recruiting Phase 1 Interventional

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

NCT04585958
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • Coral Gables, Florida • Deerfield Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Completed Phase 1 Interventional

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

NCT01623349
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer
Interventions
BKM120 and Olaparib, BYL719 and Olaparib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 10, 2026, 11:33 AM EDT
Recruiting Phase 2 Interventional

Pembro With Radiation With or Without Olaparib

NCT05568550
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pembrolizumab, Olaparib, Androgen Deprivation Therapy, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
Zin W Myint
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Lexington, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

NCT02769962
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Cancer, Lung Neoplasms, Small Cell Lung Cancer, Prostate Cancer
Interventions
EP0057, olaparib, CT scan, CT chest, abdomen, and pelvis, Bone scan, ECG, Echocardiogram, Biopsy
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Active, not recruiting Phase 2 Interventional

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03579316
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Adavosertib, Olaparib, Ceralasertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

NCT03732820
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
olaparib, abiraterone acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy

NCT04666740
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Homologous Recombination Deficiency (HRD)
Interventions
Pembrolizumab, Olaparib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 10, 2026, 11:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

NCT03334617
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, Cediranib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
17
States / cities
Duarte, California • Fullerton, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 10, 2026, 11:33 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

NCT02571725
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Olaparib, Tremelimumab
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Tampa, Florida • Albuquerque, New Mexico • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 10, 2026, 11:33 AM EDT
Completed Phase 2 Interventional

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

NCT03263650
View directory record Official record
Conditions
Prostate Cancer Aggressiveness, Prostate Carcinoma
Interventions
Cabazitaxel, Carboplatin, Prednisone 5Mg, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 10, 2026, 11:33 AM EDT